Has Phillip Fleshner, MD received payments from drug or device companies?

Yes. Drug and device makers reported $95,118 in general payments to Phillip Fleshner, MD across 132 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Phillip Fleshner, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Phillip Fleshner, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Phillip Fleshner, MD

Colon & Rectal Surgery · West Hollywood, CANPI 1881695286

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $69,752 of the $95,118 with a category attached, or 73.3%. 24 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 52.1% of the total. Among colon & rectal surgery clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$95,118in general payments, 2019–2025

Across 132 payments — averaging $720.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Takeda Pharmaceuticals U.S.A., Inc.$50K
Olympus Corporation$25K
Applied Medical Resources Corporation$6K
Intuitive Surgical$5K
Vioptix Inc$3K
Davol Inc.$2K
plus $5K from 18 others

$493,234in research payments, 2019–2025

Across 180 payments — averaging $2740.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Takeda Pharmaceuticals U.S.A., Inc.$475K
Applied Medical Resources Corporation$19K

What the payments were for

Consulting fees$69,75273%
Speaking & faculty fees$4,3355%
Travel & lodging$14,24415%
Food & beverage$2,7873%
Education$4,0004%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Takeda Pharmaceuticals U.S.A., Inc.	34	$49,559
Olympus Corporation	19	$24,831
Applied Medical Resources Corporation	1	$6,000
Intuitive Surgical	7	$4,797
Vioptix Inc	2	$2,526
Davol Inc.	2	$2,272
Olympus Corporation Of The Americas	8	$1,666
AbbVie	7	$942
Medtronic(2 entities)	16	$807
Prescient Surgical	14	$786
BD	1	$400
Axonics, Inc.	3	$108
Merck	4	$67
Baxter Healthcare	1	$60
Biotissue Holdings Inc.	2	$48
Ferring Pharmaceuticals Inc.	1	$42
Integra Lifesciences Corporation	2	$41
Acell, Inc.	2	$34
Vertex	1	$30
Kowa Pharmaceuticals America, Inc.	1	$25
Boston Scientific	1	$23
Teleflex LLC	1	$21
Cook Medical LLC	1	$18
Johnson & Johnson	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$95,118 in reported general payments places this provider in the 95th percentile of 176 colon & rectal surgery providers in California.

See all colon & rectal surgery providers in California →

Medicare billing

Part B allowed, 2024

$1,275,188

Medicare patients

838

Services billed

5,967

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Ciprofloxacin Hcl	35	$344
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine	18	$299
Hydrocortisone	23	$242
Procto-Med HcHydrocortisone	14	$92

Paid to pharmacies, not to this prescriber.

Other colon & rectal surgery in West Hollywood

Sang LeeLos Angeles$2.4M
Pamela LeeSan Diego$544K
Elizabeth RaskinSacramento$126K
Shohrat AnnaberdyevRoseville$101K
Alessio PigazziLos Angeles$100K
Joseph CarmichaelOrange$99K
Zuri MurrellBeverly Hills$86K
Lorenc MalellariBakersfield$78K
Ankit SarinSacramento$60K
Kevork KazanjianLos Angeles$37K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →